Investors poured $33.8 billion into U.S. stocks in the past week, with funds collecting the third-largest weekly haul since ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...
AN ACTION-PACKED week on Wall Street ends with a bang as index-tracking funds are set to reshuffle US$250 billion of shares, ...